SkinBioTherapeutics PLC (AIM:SBTX) CEO Stuart Ashman talked with Proactive's Stephen Gunnion about the company's strong financial and strategic progress in 2025. Ashman highlighted a 284% increase in revenue to £4.6 million, a 319% rise in gross profit, and a 62% reduction in operating losses, noting the results were in line with market expectations. He said, “We’ve achieved pretty much exactly what was expected by the market.” The company advanced its five-pillar skin health strategy, with particular developments in cosmetics and gut-skin axis supplements. Its cosmetic ingredient SkinBiotix, branded as Zenakine by partner Croda, launched in April and is generating strong industry interest, including winning an award at the In-Cosmetics Asia event. Additionally, AxisBiotix products targeting acne and psoriasis were launched through an exclusive two-year deal with Superdrug, now available in 180 stores with plans for wider rollout. SkinBioTherapeutics also progressed its acquisition strategy, integrating Dermonix and Bio-Tech Solutions. Ashman noted these contributed meaningful revenue and manufacturing capability, strengthening internal operations and product development. Looking ahead, the company expects £6.2 million in revenue and £700,000 in adjusted EBITDA for the next financial year, maintaining confidence in future growth. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and turn on notifications to stay up to date. ` #SkinBioTherapeutics #SkinHealth #Biotech #Croda #Zenakine #AxisBiotix #Dermonix #Superdrug #SkincareInnovation #Microbiome #LifeSciences #InvestorUpdate #ProactiveInvestors